Article
Clinical Neurology
Tobias Moser, Georg Zimmermann, Anna Baumgartner, Thomas Berger, Gabriel Bsteh, Franziska Di Pauli, Christian Enzinger, Elisabeth Fertl, Thomas Heller, Stefan Koppi, Paulus S. Rommer, Georg Safoschnik, Thomas Seifert-Held, Robert Stepansky, Johann Sellner
Summary: This study analyzed the course of multiple sclerosis (MS) patients in Austria after progressive multifocal leukoencephalopathy (PML) recovery and the long-term outcome of NAT-associated PML (NAT-PML). The study found that the number of NAT-PML cases is decreasing over time, and while many patients accumulated severe persistent neurological deficits after PML recovery, there was rare inflammatory MS-related disease activity.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Christoph Mahler, Adrian-Minh Schumacher, Marcus Unterrainer, Lena Kaiser, Thomas Hollbacher, Simon Lindner, Joachim Havla, Birgit Ertl-Wagner, Maximilian Patzig, Klaus Seelos, Julia Neitzel, Matthias Maurer, Markus Krumbholz, Imke Metz, Wolfgang Bruck, Christine Stadelmann, Doron Merkler, Achim Gass, Vladimir Milenkovic, Peter Bartenstein, Nathalie L. Albert, Tania Kuempfel, Martin Kerschensteiner
Summary: The study evaluated the use of TSPO PET imaging to monitor CNS inflammation in natalizumab-associated PML lesions and distinguish them from multiple sclerosis lesions, showing potential for longitudinal monitoring of disease activity and differentiation of MS activity from PML progression.
Article
Clinical Neurology
Alyssa A. Toorop, Zoe Y. G. van Lierop, Eva E. M. Strijbis, Charlotte E. Teunissen, Axel Petzold, Mike P. Wattjes, Frederik Barkhof, Brigit A. de Jong, Zoe L. E. van Kempen, Joep Killestein
Summary: Two patients with relapsing-remitting MS developed carryover PML after switching from natalizumab to ocrelizumab. Despite mild immune reconstitution inflammatory syndrome (IRIS) and increasing NfL levels, PML-IRIS lesions stabilized after treatment and both patients continued therapy with ocrelizumab.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2021)
Article
Clinical Neurology
Markus Kinner, Christian Prehn, Ruth Schneider, Christoph Schroeder, Eva Kolb, Ralf Gold, Robert Hoepner, Andew Chan
Summary: This study evaluated the neuropsychological disease course of NTZ-PML patients and found that working memory and visuospatial abilities are core deficits. NTZ-PML patients performed worse in neuropsychological examinations compared to controls, especially affecting visuospatial ability and working memory during different disease stages.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Manel Alleg, Morgane Solis, Seyyid Baloglu, Francois Cotton, Philippe Kerschen, Bertrand Bourre, Guido Ahle, Jean-Pierre Pruvo, Xavier Leclerc, Patrick Vermersch, Caroline Papeix, Elisabeth Maillart, Caroline Houillier, Cecile Molucon Chabrot, Beatrice Claise, Sandra Malak, Guillaume Martin-Blondel, Fabrice Bonneville, Alexis Caulier, Jean-Pierre Marolleau, Jerome Tamburini Bonnefoy, Philippe Agape, Celine Kennel, Xavier Roussel, Adrien Chauchet, Jerome De Seze, Samira Fafi-Kremer, Stephane Kremer
Summary: The study compared brain MRI findings in PML associated with rituximab, natalizumab treatments, and HIV infection. Different imaging features were observed in the three types of PML, with natalizumab-associated PML showing more inflammatory signs and cortex involvement, while rituximab and HIV-associated PML exhibited milder contrast enhancement and punctuate appearance. The differences in MRI findings may be related to varying levels of immunosuppression in the different patient groups.
EUROPEAN RADIOLOGY
(2021)
Review
Clinical Neurology
Nora Moehn, Lea Grote-Levi, Franziska Hopfner, Britta Eiz-Vesper, Britta Maecker-Kolhoff, Clemens Warnke, Kurt-Wolfram Suehs, Mike P. Wattjes, Guenter U. Hoeglinger, Thomas Skripuletz
Summary: Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral disease of the brain caused by human polyomavirus 2. It affects patients with compromised immune systems and currently has no effective treatment. The primary therapeutic strategy focuses on reconstituting the immune system, with recent studies showing promising effects with anti-PD-1 antibodies and allogeneic virus-specific T cells.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Gautier Breville, Igor J. Koralnik, Patrice H. Lalive
Summary: Isolated brainstem lesions at disease onset are extremely rare in PML cases, with most patients experiencing initial clinical worsening. However, some patients may achieve full or partial recovery despite the reserved prognosis due to the vital structures in the brainstem.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Biochemistry & Molecular Biology
Roberto De Masi, Stefania Orlando, Silvia Armenise, Pantaleo Spagnolo, Ruggero Capra, Maria Carmela Costa
Summary: This case report investigates a Natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML) with cerebellar localization and wakefulness disturbances. The study shows that awakening and clinical improvement occurred dramatically with the onset of immune reconstitution inflammatory syndrome (IRIS), which was mild in nature and colocalized with the PML lesion. MRI analysis revealed an increase in white matter volume and a decrease in grey matter during IRIS, while the cerebrospinal fluid volume consistently increased throughout the duration of PML. The brain parenchymal fraction decreased as expected, but the total brain volume remained stable. Neurodegeneration, supported by IRIS and humoral factors derived from the PML lesion, is believed to be the main cause of steady disability in Natalizumab-associated PML.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Marine Joly, Cecile Conte, Charles Cazanave, Vincent Le Moing, Pierre Tattevin, Pierre Delobel, Agnes Sommet, Guillaume Martin-Blondel
Summary: This study examined the epidemiology and prognosis of progressive multifocal leukoencephalopathy using a large cohort of patients in France. The findings revealed a stable incidence rate of the disease in France, with HIV infection being the main predisposing condition. Male patients had a higher risk of mortality compared to females, and patients with solid neoplasms had the worst prognosis.
Article
Medicine, General & Internal
Viviana Lo Buono, Giangaetano D'Aleo, Simona Cammaroto, Maria Cristina De Cola, Francesca Palmese, Chiara Smorto, Silvia Marino, Giuseppe Venuti, Edoardo Sessa, Carmela Rifici, Francesco Corallo
Summary: This study reports a case of PML related to natalizumab and describes the longitudinal course of the disease, documenting the progressive deterioration of the patient's cognitive functioning. The findings expand the range of treatment-related complications associated with natalizumab and provide evidence for the early diagnosis of PML.
MEDICINA-LITHUANIA
(2022)
Article
Medicine, General & Internal
Varun Jain, Hannah Branstetter, Srikar Savaram, Matthew Vasquez, Gabriel Swords, Sina Aghili-Mehrizi, John Rees, Marie Rivera-Zengotita, Mayra Montalvo, Miguel Chuquilin, Addie Patterson, Torge Rempe
Summary: This study is a retrospective review of all PML cases at the University of Florida. The results suggest that PML without overt immunosuppression may be more common than previously described. Therefore, PML should be considered even in the absence of overt immunosuppression.
Review
Virology
Shitiz Sriwastava, Erum Khan, Syed H. Khalid, Arshdeep Kaur, Parissa Feizi
Summary: Progressive multifocal leukoencephalopathy (PML) is typically seen in immunocompromised patients, but our case demonstrates its rare occurrence in immunocompetent individuals. Furthermore, our literature review indicates that patients respond well to mirtazapine and intravenous pulse methylprednisolone (IVMP).
JOURNAL OF MEDICAL VIROLOGY
(2022)
Review
Clinical Neurology
Laura E. Baldassari, Mike P. Wattjes, Irene C. M. Cortese, Achim Gass, Imke Metz, Tarek Yousry, Daniel S. Reich, Nancy Richert
Summary: Progressive multifocal leukoencephalopathy (PML) is a CNS infection caused by the JC virus. MRI is an important tool for detecting PML, showing the location and extent of lesions, as well as reflecting the disease progression and inflammation. Currently, there are no validated imaging-based outcome measures for use in PML clinical trials.
Article
Clinical Neurology
Nicolas Lambert, Majdouline El Moussaoui, Pierre Maquet
Summary: This study investigated the response of patients with Progressive multifocal leukoencephalopathy (PML) to immune checkpoint inhibitors (ICI). It was found that a history of therapeutic immune suppression and the use of an immunosuppressive therapy at treatment initiation were significantly associated with a poor response. Reaching an undetectable viral load in the cerebrospinal fluid and reduction of lesion load on magnetic resonance imaging after ICI administration were associated with a good clinical response.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Multidisciplinary Sciences
Jinnam Kim, Changhyup Kim, Jung Ah Lee, Se Ju Lee, Ki Hyun Lee, Jung Ho Kim, Jin Young Ahn, Su Jin Jeong, Nam Su Ku, Jun Yong Choi, Joon-Sup Yeom, Young Goo Song
Summary: Progressive multifocal leukoencephalopathy (PML) is a rare but fatal opportunistic infection mainly occurring in patients with immunosuppressive conditions. Retrospective studies have shown that the survival rate of PML patients is related to HIV infection, and early diagnosis and treatment can improve prognosis.
SCIENTIFIC REPORTS
(2023)
Letter
Clinical Neurology
Massimiliano Di Filippo, Cinzia Cordioli, Simona Malucchi, Pietro Annovazzi, Paola Cavalla, Valentina Torri Clerici, Paolo Ragonese, Viviana Nociti, Marta Radaelli, Alice Laroni, Fabio Buttari, Lorena Lorefice, Diana Ferraro, Alberto Gajofatto, Luca Prosperini, Roberta Fantozzi, Laura Boffa, Roberta Lanzillo, Marcello Moccia, Marinella Clerico, Giovanna De Luca, Valentina Tomassini, Massimiliano Calabrese, Angela Borrelli, Damiano Paolicelli, Giorgia Teresa Maniscalco, Paola Gazzola, Antonio Gallo, Claudio Solaro, Eleonora Cocco, Claudio Gasperini, Carla Tortorella
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Clinical Neurology
Maria Pia Sormani, Irene Schiavetti, Doriana Landi, Luca Carmisciano, Nicola De Rossi, Cinzia Cordioli, Lucia Moiola, Marta Radaelli, Paolo Immovilli, Marco Capobianco, Vincenzo Brescia Morra, Maria Trojano, Gioacchino Tedeschi, Giancarlo Comi, Mario Alberto Battaglia, Francesco Patti, Yara Dadalti Fragoso, Sedat Sen, Aksel Siva, Roberto Furlan, Marco Salvetti
Summary: The study assessed the relationship between disease-modifying therapy (DMT) and the development of anti-SARS-CoV-2 antibodies in patients with multiple sclerosis (MS), finding that patients treated with anti-CD20 drugs had a lower likelihood of developing antibodies.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Luigi Lavorgna, Pietro Iaffaldano, Gianmarco Abbadessa, Roberta Lanzillo, Sabrina Esposito, Domenico Ippolito, Maddalena Sparaco, Simone Cepparulo, Giacomo Lus, Rosa Viterbo, Marinella Clerico, Francesca Trojsi, Paolo Raganose, Giovanna Borriello, Elisabetta Signoriello, Raffaele Palladino, Marcello Moccia, Francesco Brigo, Maria Troiano, Gioacchino Tedeschi, Simona Bonavita
Summary: The study found discrepancies in AS and EDSS assessments between GM (R) and routine clinical methods in 243 patients with multiple sclerosis. Progressive phenotype, worse fatigue, and more severe depression were associated with discrepancies between GM (R) and routine clinical scoring.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Cinzia Valeria Russo, Francesco Sacca, Jessica Frau, Pietro Annovazzi, Elisabetta Signoriello, Simona Bonavita, Roberta Grasso, Marinella Clerico, Cinzia Cordioli, Alice Laroni, Marco Capobianco, Valentina Torri Clerici, Arianna Sartori, Paola Cavalla, Giorgia Teresa Maniscalco, Sara La Gioia, Francesca Caleri, Alessia Giugno, Rosa Iodice, Antonio Carotenuto, Eleonora Cocco, Giuseppe Fenu, Mauro Zaffaroni, Damiano Baroncini, Giacomo Lus, Antonio Gallo, Stefania Federica De Mercanti, Caterina Lapucci, Valeria Di Francescantonio, Laura Brambilla, Maria Pia Sormani, Alessio Signori
Summary: The study provided real-world data on the impact of clinical variables and previous therapies on the effectiveness of alemtuzumab in multiple sclerosis patients. It showed a significant decrease in annualized relapse rate and improvement in disability status after treatment with alemtuzumab, independent of previous disease-modifying therapies. Overall, the majority of patients exhibited no disease progression after 2 years of alemtuzumab treatment, with a notable percentage showing improvement in their condition.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Giuseppina Miele, Luigi Lavorgna, Stefania Federica De Mercanti, Marco Iudicello, Gianmarco Abbadessa, Manuela Matta, Simona Bonavita, Marinella Clerico
Summary: Friedreich's ataxia is a debilitating disease that significantly affects the quality of life for both patients and caregivers. The main sources of information for both patients and caregivers are FRDA specialists and the media, with a particular interest in general information and both existing and experimental therapies. Understanding the information-seeking behavior of FRDA patients and caregivers can lead to tailored information and improved therapeutic alliance.
NEUROLOGICAL SCIENCES
(2022)
Correction
Clinical Neurology
Luigi Lavorgna, Pietro Iaffaldano, Gianmarco Abbadessa, Roberta Lanzillo, Sabrina Esposito, Domenico Ippolito, Maddalena Sparaco, Simone Cepparulo, Giacomo Lus, Rosa Viterbo, Marinella Clerico, Francesca Trojsi, Paolo Ragonese, Giovanna Borriello, Elisabetta Signoriello, Raffaele Palladino, Marcello Moccia, Francesco Brigo, Maria Troiano, Gioacchino Tedeschi, Simona Bonavita
NEUROLOGICAL SCIENCES
(2022)
Review
Psychology, Multidisciplinary
Marialaura Di Tella, Marinella Clerico, Lorys Castelli
Summary: This scoping review systematically reviews the association between socioemotional alterations and reduced quality of life (QoL) and social functioning in patients with Multiple Sclerosis (MS). Eight studies fulfilling the inclusion criteria were included in the review, and the majority of findings suggest that socioemotional alterations contribute to impaired QoL and social functioning in MS patients. However, more research is needed to replicate and confirm these findings, particularly with standardized and ecological tasks for assessing social cognition skills and diverse samples of MS patients.
CURRENT PSYCHOLOGY
(2023)
Letter
Clinical Neurology
Alessandro Maglione, Marta Morra, Raffaella Meroni, Manuela Matta, Marinella Clerico, Simona Rolla
Summary: In this study, the production of antireceptor binding domain (RBD) Immunoglobulins G (IgG) after the vaccination cycle and booster was evaluated in people with multiple sclerosis (pwMS) receiving ocrelizumab, fingolimod, and cladribine. The results showed a significant increase in anti-RBD IgG seroconversion after the booster.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Immunology
Simona Rolla, Stefania Federica De Mercanti, Valentina Bardina, Alessandro Maglione, Daniela Taverna, Francesco Novelli, Eleonora Cocco, Anton Vladic, Mario Habek, Ivan Adamec, Pietro Osvaldo Luigi Annovazzi, Dana Horakova, Marinella Clerico
Summary: Alemtuzumab has long-term efficacy in the treatment of patients with relapsing multiple sclerosis by increasing the percentage of Treg cells, restoring their suppressor function, and reducing the number of self-reactive cells through immune regulation. These findings contribute to a better understanding of the therapeutic mechanism of alemtuzumab.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Maria Pia Sormani, Irene Schiavetti, Matilde Inglese, Luca Carmisciano, Alice Laroni, Caterina Lapucci, Valeria Visconti, Carlo Serrati, Ilaria Gandoglia, Tiziana Tassinari, Germana Perego, Giampaolo Brichetto, Paola Gazzola, Antonio Mannironi, Maria Laura Stromillo, Cinzia Cordioli, Doriana Landi, Marinella Clerico, Elisabetta Signoriello, Eleonora Cocco, Jessica Frau, Maria Teresa Ferro, Alessia Di Sapio, Livia Pasquali, Monica Ulivelli, Fabiana Marinelli, Matteo Pizzorno, Graziella Callari, Rosa Iodice, Giuseppe Liberatore, Francesca Caleri, Anna Maria Repice, Susanna Cordera, Mario Alberto Battaglia, Marco Salvetti, Diego Franciotta, Antonio Uccelli
Summary: This study aimed to monitor the risk of breakthrough SARS-CoV-2 infection in patients with MS under different DMTs and identify correlates of reduced protection. The results showed that reduced levels of virus-specific humoral immune response were associated with an increased risk of breakthrough infection.
Article
Cell Biology
Sofia Passaponti, Leonardo Ermini, Giulia Acconci, Filiberto Maria Severi, Roberta Romagnoli, Santina Cutrupi, Marinella Clerico, Gisella Guerrera, Francesca Ietta
Summary: This study demonstrates the influence of late pregnancy on the balance between RANKL and OPG in women with multiple sclerosis (MS), and identifies the placenta as an important source of homodimeric OPG. Placental OPG suppresses the mRNA expression of CCL20 and affects the recruitment of Th17 cells. Therefore, placental OPG may play a crucial role in the beneficial effects of late pregnancy on MS, and could potentially be used for the development of new and more effective therapeutic approaches.
Article
Clinical Neurology
Irene Schiavetti, Cinzia Cordioli, Maria Laura Stromillo, Maria Teresa Ferro, Alice Laroni, Eleonora Cocco, Gaia Cola, Livia Pasquali, Maria Teresa Rilla, Elisabetta Signoriello, Rosa Iodice, Alessia Di Sapio, Roberta Lanzillo, Francesca Caleri, Pietro Annovazzi, Antonella Conte, Giuseppe Liberatore, Francesca Ruscica, Renato Docimo, Simona Bonavita, Monica Ulivelli, Paola Cavalla, Francesco Patti, Diana Ferraro, Marinella Clerico, Paolo Immovilli, Massimiliano Di Filippo, Marco Salvetti, Maria Pia Sormani
Summary: Patients with multiple sclerosis treated with ocrelizumab and fingolimod have a higher risk of breakthrough SARS-CoV-2 infections, while the rate of severe infections is significantly lower in all disease-modifying therapy groups excluding ocrelizumab.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Irene Schiavetti, Luca Carmisciano, Marta Ponzano, Cinzia Cordioli, Eleonora Cocco, Girolama Alessandra Marfia, Matilde Inglese, Massimo Filippi, Marta Radaelli, Roberto Bergamaschi, Paolo Immovilli, Marco Capobianco, Nicola De Rossi, Giampaolo Brichetto, Cinzia Scandellari, Paola Cavalla, Ilaria Pesci, Paolo Confalonieri, Paola Perini, Maria Trojano, Roberta Lanzillo, Gioacchino Tedeschi, Giancarlo Comi, Mario Alberto Battaglia, Francesco Patti, Marco Salvetti, Maria Pia Sormani
Summary: The study found that the most common symptoms of COVID-19 in multiple sclerosis patients are ageusia and anosmia, which are often associated with smoking, substance abuse, conjunctivitis, and other comorbidities. Certain disease-modifying therapies may also impact the occurrence of COVID-19 symptoms.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Doriana Landi, Francesca Bovis, Alfonso Grimaldi, Pietro Osvaldo Annovazzi, Antonio Bertolotto, Alessia Bianchi, Giovanna Borriello, Vincenzo Brescia Morra, Sebastiano Bucello, Maria Chiara Buscarinu, Francesca Caleri, Marco Capobianco, Ruggero Capra, Maria Cellerino, Diego Centonze, Raffaella Cerqua, Clara Grazia Chisari, Marinella Clerico, Eleonora Cocco, Gaia Cola, Cinzia Cordioli, Erica Curti, Alessandro d'Ambrosio, Emanuele D'Amico, Giovanna De Luca, Massimiliano Di Filippo, Sonia Di Lemme, Roberta Fantozzi, Diana Ferraro, Elisabetta Ferraro, Antonio Gallo, Claudio Gasperini, Franco Granella, Matilde Inglese, Roberta Lanzillo, Lorena Lorefice, Giacomo Lus, Simona Malucchi, Monica Margoni, Giorgia Mataluni, Massimiliano Mirabella, Lucia Moiola, Carolina Gabri Nicoletti, Viviana Nociti, Francesco Patti, Federica Pinardi, Emilio Portaccio, Carlo Pozzilli, Paolo Ragonese, Sarah Rasia, Giuseppe Salemi, Elisabetta Signoriello, Francesca Vitetta, Rocco Totaro, Maria Pia Sormani, Maria Pia Amato, Girolama Alessandra Marfia
Summary: The study found that continuing natalizumab treatment throughout pregnancy and resuming it early after delivery can reduce the risk of clinical and radiological reactivation in women with multiple sclerosis. This approach has no major impact on newborns' outcomes.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Computer Science, Interdisciplinary Applications
Simone Pernice, Alessandro Maglione, Dora Tortarolo, Roberta Sirovich, Marinella Clerico, Simona Rolla, Marco Beccuti, Francesca Cordero
Summary: GreatNector workflow is a valuable tool for analyzing and clustering patient-derived longitudinal data, as well as simulating the resulting model of patient-specific disease dynamics. The analysis was able to stratify individual patients into three model meta-patients, providing insight into patient-tailored interventions. The results showed that T-cell dynamics after alemtuzumab treatment separate non-responders versus responders patients, with non-responders group characterized by an increase of the Th17 concentration around 36 months.
JOURNAL OF BIOMEDICAL INFORMATICS
(2023)
